Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
610 in severe eosinophilic asthma
NCT06323213Phase 3Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of 610 in asthma, sponsored by 3S Guojian Pharmaceutical. Started Jun 2024; status: recruiting.
02
Drugs
610
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06323213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323213.